MONOCLONAL ANTIBODIES AGAINST RGM PROTEIN FOR USE IN TREATMENT OF RETINAL NERVE FIBER LAYER DEGENERATION

To provide antibodies that can bind to RGM A of RNFL degeneration observed in a multiplicity of disease conditions.SOLUTION: The invention provides a RGM A binding protein having an ability to bind to RGM A to inhibit the binding of RGM protein to RGM A receptor and other RGM A binding proteins and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	MULLER BERNHARD K
Format:	Patent
Sprache:	eng ; jpn
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	MULLER BERNHARD K
description	To provide antibodies that can bind to RGM A of RNFL degeneration observed in a multiplicity of disease conditions.SOLUTION: The invention provides a RGM A binding protein having an ability to bind to RGM A to inhibit the binding of RGM protein to RGM A receptor and other RGM A binding proteins and therefore to neutralize the function of RGM A, particularly a monoclonal antibody, in particular, a CDR grafted and humanized version thereof for use in treatment of retinal nerve fiber layer degeneration. The invention also provides a method for therapeutically or prophylactically treating a mammal against RNFL degeneration.SELECTED DRAWING: None 【課題】多数の病状で観察されるＲＮＦＬ変性のＲＧＭＡに結合できる抗体の提供。【解決手段】網膜神経線維層（ＲＮＦＬ）変性の治療に使用するためのＲＧＭＡに結合し、ＲＧＭタンパク質のＲＧＭＡ受容体及び他のＲＧＭＡ結合タンパク質に対する結合を妨げ、よってＲＧＭＡの機能を中和する能力を有するＲＧＭＡ結合タンパク質、特にモノクローナル抗体、とりわけそのＣＤＲグラフト化ヒト化バージョン、並びにＲＮＦＬ変性を防ぐために哺乳動物を治療上または予防上治療する方法を提供する。【選択図】なし
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2019059731A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2019059731A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2019059731A3</originalsourceid><addsrcrecordid>eNqNi8EKglAQRd20iOofhvaBJhEuR51nL3RG3puCViLxokWUYP9PBn1Am3sPl3Pn0b0RlqIWxhqQ1eZSWvKAFVr2Cq5qoHWiZBmMODh5ggnVEWpDrCAGHKn93pncmcDYnBzUeJmypIqmFdUKL6PZrX-MYfXrRbQ2pMVhE4ZXF8ahv4ZneHfHdhsnWbzL9mmC6V_SB4qANgw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MONOCLONAL ANTIBODIES AGAINST RGM PROTEIN FOR USE IN TREATMENT OF RETINAL NERVE FIBER LAYER DEGENERATION</title><source>esp@cenet</source><creator>MULLER BERNHARD K</creator><creatorcontrib>MULLER BERNHARD K</creatorcontrib><description>To provide antibodies that can bind to RGM A of RNFL degeneration observed in a multiplicity of disease conditions.SOLUTION: The invention provides a RGM A binding protein having an ability to bind to RGM A to inhibit the binding of RGM protein to RGM A receptor and other RGM A binding proteins and therefore to neutralize the function of RGM A, particularly a monoclonal antibody, in particular, a CDR grafted and humanized version thereof for use in treatment of retinal nerve fiber layer degeneration. The invention also provides a method for therapeutically or prophylactically treating a mammal against RNFL degeneration.SELECTED DRAWING: None 【課題】多数の病状で観察されるＲＮＦＬ変性のＲＧＭＡに結合できる抗体の提供。【解決手段】網膜神経線維層（ＲＮＦＬ）変性の治療に使用するためのＲＧＭＡに結合し、ＲＧＭタンパク質のＲＧＭＡ受容体及び他のＲＧＭＡ結合タンパク質に対する結合を妨げ、よってＲＧＭＡの機能を中和する能力を有するＲＧＭＡ結合タンパク質、特にモノクローナル抗体、とりわけそのＣＤＲグラフト化ヒト化バージョン、並びにＲＮＦＬ変性を防ぐために哺乳動物を治療上または予防上治療する方法を提供する。【選択図】なし</description><language>eng ; jpn</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190418&DB=EPODOC&CC=JP&NR=2019059731A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190418&DB=EPODOC&CC=JP&NR=2019059731A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MULLER BERNHARD K</creatorcontrib><title>MONOCLONAL ANTIBODIES AGAINST RGM PROTEIN FOR USE IN TREATMENT OF RETINAL NERVE FIBER LAYER DEGENERATION</title><description>To provide antibodies that can bind to RGM A of RNFL degeneration observed in a multiplicity of disease conditions.SOLUTION: The invention provides a RGM A binding protein having an ability to bind to RGM A to inhibit the binding of RGM protein to RGM A receptor and other RGM A binding proteins and therefore to neutralize the function of RGM A, particularly a monoclonal antibody, in particular, a CDR grafted and humanized version thereof for use in treatment of retinal nerve fiber layer degeneration. The invention also provides a method for therapeutically or prophylactically treating a mammal against RNFL degeneration.SELECTED DRAWING: None 【課題】多数の病状で観察されるＲＮＦＬ変性のＲＧＭＡに結合できる抗体の提供。【解決手段】網膜神経線維層（ＲＮＦＬ）変性の治療に使用するためのＲＧＭＡに結合し、ＲＧＭタンパク質のＲＧＭＡ受容体及び他のＲＧＭＡ結合タンパク質に対する結合を妨げ、よってＲＧＭＡの機能を中和する能力を有するＲＧＭＡ結合タンパク質、特にモノクローナル抗体、とりわけそのＣＤＲグラフト化ヒト化バージョン、並びにＲＮＦＬ変性を防ぐために哺乳動物を治療上または予防上治療する方法を提供する。【選択図】なし</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNi8EKglAQRd20iOofhvaBJhEuR51nL3RG3puCViLxokWUYP9PBn1Am3sPl3Pn0b0RlqIWxhqQ1eZSWvKAFVr2Cq5qoHWiZBmMODh5ggnVEWpDrCAGHKn93pncmcDYnBzUeJmypIqmFdUKL6PZrX-MYfXrRbQ2pMVhE4ZXF8ahv4ZneHfHdhsnWbzL9mmC6V_SB4qANgw</recordid><startdate>20190418</startdate><enddate>20190418</enddate><creator>MULLER BERNHARD K</creator><scope>EVB</scope></search><sort><creationdate>20190418</creationdate><title>MONOCLONAL ANTIBODIES AGAINST RGM PROTEIN FOR USE IN TREATMENT OF RETINAL NERVE FIBER LAYER DEGENERATION</title><author>MULLER BERNHARD K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2019059731A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2019</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>MULLER BERNHARD K</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MULLER BERNHARD K</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MONOCLONAL ANTIBODIES AGAINST RGM PROTEIN FOR USE IN TREATMENT OF RETINAL NERVE FIBER LAYER DEGENERATION</title><date>2019-04-18</date><risdate>2019</risdate><abstract>To provide antibodies that can bind to RGM A of RNFL degeneration observed in a multiplicity of disease conditions.SOLUTION: The invention provides a RGM A binding protein having an ability to bind to RGM A to inhibit the binding of RGM protein to RGM A receptor and other RGM A binding proteins and therefore to neutralize the function of RGM A, particularly a monoclonal antibody, in particular, a CDR grafted and humanized version thereof for use in treatment of retinal nerve fiber layer degeneration. The invention also provides a method for therapeutically or prophylactically treating a mammal against RNFL degeneration.SELECTED DRAWING: None 【課題】多数の病状で観察されるＲＮＦＬ変性のＲＧＭＡに結合できる抗体の提供。【解決手段】網膜神経線維層（ＲＮＦＬ）変性の治療に使用するためのＲＧＭＡに結合し、ＲＧＭタンパク質のＲＧＭＡ受容体及び他のＲＧＭＡ結合タンパク質に対する結合を妨げ、よってＲＧＭＡの機能を中和する能力を有するＲＧＭＡ結合タンパク質、特にモノクローナル抗体、とりわけそのＣＤＲグラフト化ヒト化バージョン、並びにＲＮＦＬ変性を防ぐために哺乳動物を治療上または予防上治療する方法を提供する。【選択図】なし</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng ; jpn
recordid	cdi_epo_espacenet_JP2019059731A
source	esp@cenet
subjects	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	MONOCLONAL ANTIBODIES AGAINST RGM PROTEIN FOR USE IN TREATMENT OF RETINAL NERVE FIBER LAYER DEGENERATION
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T22%3A16%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MULLER%20BERNHARD%20K&rft.date=2019-04-18&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2019059731A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true